A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...